首页> 美国卫生研究院文献>Oncotarget >The clinical utility and outcomes of microwave ablation for colorectal cancer liver metastases
【2h】

The clinical utility and outcomes of microwave ablation for colorectal cancer liver metastases

机译:微波消融治疗结直肠癌肝转移的临床应用和疗效

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In recent years, the microwave ablation (MWA) has been reported to play an important role in the treatment of patients with colorectal liver metastases (CRLM). In this work, 62 cases of patients who received MWA for liver metastases from colon or rectal cancer between Jan 2012 and Jan 2014 were enrolled in this trial. 28 underwent MWA, and 34 were treated with liver resection as control. Perioperative and 60 months of follow-up data were collected to analyze potential adverse effects, concurrent conditions and survival status. Here, we found there were no significant differences between both groups in the baseline level, including gender, size, number and pathological type (all p>0.05). In those patients, the mean hospitalization duration of patients with MWA is 5.9±0.9d, which is significantly different from control (11.8±6.9 d) (p<0.001). Little severe complication was observed in MWA group, while 26.5% (9/34) of patients developed severe complications (p=0.003). Besides, the mean hospitalization cost of patients with MWA was significantly less than that of control (p<0.000). Additionally, we found no statistically significant differences in disease-free survival (DFS) (p=0.156) or overall survival (OS) (p=0.580). In conclusion, MWA may be a safe, economical and competent way to treat inoperable CRLM patients, which has more advantages than liver resection in some degree.
机译:近年来,有报道说微波消融(MWA)在大肠肝转移患者(CRLM)的治疗中起着重要作用。在这项工作中,本研究纳入了2012年1月至2014年1月之间因结肠癌或直肠癌肝转移而接受MWA的62例患者。 28例行MWA,34例行肝脏切除术作为对照。收集围手术期和60个月的随访数据,以分析潜在的不良反应,并发情况和生存状况。在这里,我们发现两组在基线水平上没有显着差异,包括性别,大小,数量和病理类型(均p> 0.05)。在这些患者中,MWA患者的平均住院时间为5.9±0.9 d,与对照组的平均住院时间(11.8±6.9 d)显着不同(p <0.001)。在MWA组中几乎没有观察到严重并发症,而26.5%(9/34)的患者出现了严重并发症(p = 0.003)。此外,MWA患者的平均住院费用显着低于对照组(p <0.000)。此外,我们发现无病生存期(DFS)(p = 0.156)或总生存期(OS)(p = 0.580)在统计学上没有显着差异。总之,MWA可能是治疗无法手术的CRLM患者的一种安全,经济和有效的方法,在某种程度上比肝切除术具有更多的优势。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号